A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
Novo Nordisk · Obesity · Heart Failure
Phase 3
Recruiting
5,610
2026-07
Evidence dashboardStudies since 2022Updated Jul 31, 2026
AmycretinClinical Trials.
A source-linked view of every Amycretin study in the current snapshot—status, phase, enrollment, results, publications, locations and changes over time.
- Total trials
- 21
- Recruiting
- 10
- Completed
- 9
- Terminated
- 0
- Results posted
- 0
- Average enrollment
- 555
- Countries
- 34
- Highest phase
- Phase 3
Largest indexed study
5,610 participants · NCT07567001 →Developer / research origin
Novo Nordisk
Evidence summary
Activity is not efficacy.
Amycretin appears in 21 indexed studies: 10 recruiting, 9 completed and 0 with registry results posted. The highest registered development stage in this snapshot is Phase 3. These counts measure registry activity; they do not establish that Amycretin is safe or effective.
Review the design, endpoints, population, protocol changes, statistical analysis and publications before drawing conclusions.
Current studies
Recruiting or active
Completed studies
Finished records
Stopped studies
Withdrawn or terminated
NCT IDStudyPhase / statusEnrollmentUpdated
AMAZE 3: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Not Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea
Novo Nordisk · Obesity · Overweight
Phase 3
Recruiting
300
2026-07
AMAZE 4: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea
Novo Nordisk · Obesity · Overweight
Phase 3
Recruiting
300
2026-07
AMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose Weight
Novo Nordisk · Obesity
Phase 3
Recruiting
1,150
2026-07
A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain
Novo Nordisk · Obesity · Knee Osteoarthritis (OA)
Phase 3
Recruiting
400
2026-07
AMAZE 12: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Maintain Their Weight Loss
Novo Nordisk · Obesity
Phase 3
Recruiting
600
2026-07
Showing 6 of 12 studies
NCT IDStudyPhase / statusEnrollmentUpdated
A Research Study on How NNC0487-0111, a New Medicine, Works in Chinese Participants When Injected Under the Skin.
Novo Nordisk · Overweight · Obesity
Phase 1
Completed
36
2026-02
A Research Study Comparing How Well Different Doses of the Medicine NNC0487-0111 Lower Blood Sugar in People With Type 2 Diabetes
Novo Nordisk · Type 2 Diabetes (T2D)
Phase 2
Completed
448
2025-12
A Research Study to See How a New Medicine (NNC0487-0111) Works in People With Overweight or Obesity When Injected Under the Skin
Novo Nordisk · Obesity · Overweight
Phase 2
Completed
125
2025-11
A Research Study on How NNC0487-0111, a New Medicine, Works in Chinese Participants After 10 Days of Oral Dosing
Novo Nordisk · Overweight · Obesity
Phase 1
Completed
29
2025-08
A Research Study Looking at Different Oral Formulations and the Effect of Food Intake on How the Medicine NNC0487-0111 Behaves in the Body of Participants Living With Overweight or Obesity
Novo Nordisk · Obesity · Overweight
Phase 1
Completed
133
2025-08
A Research Study on How NNC0487-0111 Works in People With Overweight or Obesity
Novo Nordisk · Obesity
Phase 1
Completed
144
2025-06
Showing 6 of 9 studies
No studies in this snapshot.
Full study index
Search Amycretin trials.
Add status, phase, condition, country, result and publication filters inside this molecule’s indexed study set.
21 matching studies
Last registry update first
Latest publications
Follow the paper trail.
PMID 40550231 ↗Dahl K, Toubro S, Dey S, Duque do Vale R, Flint A, Gasiorek A, Heydorn A, Jastreboff AM, Key C, Petersen SB, Vegge A, Adelborg K. Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study. Lancet. 2025 Jul 12;406(10499):149-162. doi: 10.1016/S0140-6736(25)01185-7. Epub 2025 Jun 20.Linked from NCT06064006PMID 40550229 ↗Gasiorek A, Heydorn A, Gabery S, Hjerpsted JB, Kirkeby K, Kruse T, Petersen SB, Toubro S, Vegge A, Key C. Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, double-blind, randomised, placebo-controlled trial. Lancet. 2025 Jul 12;406(10499):135-148. doi: 10.1016/S0140-6736(25)01176-6. Epub 2025 Jun 20.Linked from NCT05369390PMID 42443140 ↗Oldenburg LIK, Haugaard SP, Karlsson T, Kegel-Hubner V, Parwez M, Wiingaard C, Flint A. Renal Impairment Does Not Affect Pharmacokinetics, Safety or Tolerability of Zenagamtide. Diabetes Obes Metab. 2026 Jul 13. doi: 10.1111/dom.71096. Online ahead of print.Linked from NCT06559527
Related pages
Keep researching Amycretin.
Commercial research listings, where present, are kept separate from clinical evidence and are not treatment recommendations.